FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory...

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Direct: FDA Awards Six National Priority Vouchers

FDA Direct: Catching Up on Agency Reforms

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

Medical Device Quality Management System Regulation Risk Management

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

GCP & Pharmacovigilance Compliance Symposium | D3S03-1 - (BE): Clinical Study Conduct

2025 FDA Achievements

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S04 - (PV): International...

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S08 – Symposium Wrap-up and...

Medical Device Quality Management System Regulation Design and Development

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S06 - (PV): Regulatory Updates

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S07 – Q&A Discussion Panel

Public Meeting: Reauthorization of the Biosimilar User Fee Act